Ken, addressing your questions:
What numbers for how many
Ken, addressing your questions:
What numbers for how many patients do you expect to see?
What numbers? According to the poster by Rr. M. Kasi et-al (April 17-22, 2026): “Increases in CPS/PD-L1 on paired tissue and CTC/CAMLs has been observed and will be reported in a larger dataset at an upcoming conference.”.
Also, from same poster: “Primary objectives include safety and objective response rate per RECIST v1.1 criteria. Other evaluations include ctDNA kinetics, and PD-L1 expression on circulating tumor cells (CTCs) and cancer associated macrophage-like cells (CAMLs).”
So we will have (hopefully) CPS and ctDNA.
For how many patients? If full enrollment was achieved in April we should have data for all the 60 patients; ctDNA readings apart from being a "clean" biomarker can be obtained rapidly and repeatedly. Roughly, ctDNA falls around week 1-2 (week 8-12 scans will show ORR) and I don’t see a good reason not to have reports for all patients.
CPS measurement is a bit more involved as CPS does not change quickly. PD-L1 expression is driven by mechanisms such as immune activation, interferon signaling, and microenvironment remodeling, all of which take time. For CRC meaningful readings will take 2 months+ with stable readings after 3-4 months. CLOVER calls for 13 cycles of 4 weeks each (about a year) with follow-up up to two years. In October we would have around ½ year of treatment for all patients (more for some). There will be for sure readings associated with PD-L1 expression (stable). To what extent will those be shared is difficult to tell but there is enough time to have meaningful readings in October (more than 6 months after full enrollment).
As a note, In Pestell’s poster (AACR annual Meeting - April 17-22, 2026) referring to treatment for low metastatic TNBC, PD-L1, expression was reported in Relative Fluorescence Units not the best number to report due to subjectivity). Hopefully we will get CPS readings.
17
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
The Hidden Cost of Colorado's Dry Air Dry climate isn't just a seasonal inconvenience—it's a real hidden cost to living comfortably and healthily in Colorado. With winters colder than a brass monkey's tail and summers that don't offer much relief in terms of humidity, your home's air quality is on the front line. So, what's the financial tale here, and how do you come...
Continue Reading
Trouble Brews at D-Wave Quantum Smack in the middle of market chaos, D-Wave Quantum Inc. (NASDAQ: QBTS) seems to have hit a rather gnarly pothole. With disappointing revenue figures for Q2 of 2026—coming in at a measly $3.08 million, far below the expected range of $4.03 million to $4.08 million—investors have more than enough reasons to be irked. When the numbers...
Continue Reading
Why Pizza Is More Than Just Food They say a slice of pizza can tell a story. Whether it's a late-night snack amongst college buddies or the centerpiece of a family's Friday tradition, pizza unites like few others can. It morphs from a study aid into a tool for togetherness without skipping a beat, much like a chameleon of the food world. And no one understands this better...
Continue Reading
Ajman: A Tourism Gem in the Making Swinging into the Arabian Travel Market 2026, Ajman isn't just a footnote in the UAE's tourism playbook anymore, it's gunning for the spotlight. There's a flurry of activity as the Ajman Department of Tourism, Culture and Media rolls up its sleeves to flaunt the emirate's kaleidoscope of attractions to the world's tourism brass. Going...
Continue Reading
Unraveling Ellison's Bold Decision There's nothing like a sudden shift from a tech titan to make Wall Street sit up and take notice. Today, we got the word that Larry Ellison, Oracle's big gun as Executive Chair and CTO, has pulled the plug on his plan to sell Oracle stock. No dice, no distance covered under that plan. And he's made it crystal clear—selling isn't on his...
Continue Reading
The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...
Continue Reading
Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...
Continue Reading
The Rise of "Safe Ground" on Prime Video This isn't your typical feel-good story—it’s about grit and the unending fight for 'normalcy' where war left scars. Safe Ground, now streaming on Prime Video, showcases Ryan Hendrickson, a U.S. Army Green Beret whose story takes a sharp turn after stepping on an IED in 2010. The day he almost became just another statistic...
Continue Reading
Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...
Continue Reading
Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...
Continue Reading
Top 5 Most Recently Viewed Articles
IDnow and Keyless Transforming Digital Identity Security IDnow, a leading identity verification platform provider in Europe, has forged a strategic partnership with Keyless, a trailblazer in privacy-focused biometric authentication. This collaboration marks a pivotal advancement in the realm of digital identity security and seeks to enhance trustworthiness across various...
Continue Reading
Fairfax Financial Enhances Control of Brit Limited Fairfax Financial Holdings Limited (“Fairfax”) (TSX: FFH and TSX: FFH.U) has made a significant move by increasing its ownership of Brit Limited to a full 100%. This pivotal increase in ownership comes at the cost of approximately US$383 million, which Fairfax has agreed to pay to acquire the remaining shares from...
Continue Reading
Stepan Company Announces New Board Appointment Stepan Company (NYSE: SCL) has made a significant addition to its Board of Directors with the recent appointment of Corning Painter, who steps into the role effective immediately. About Corning Painter Corning Painter comes to Stepan with a robust background in the chemical manufacturing sector. He is currently the Chief...
Continue Reading
Introduction to the Emerging Issue of Online Gambling As the landscape of online gambling evolves rapidly, the rise of illegal operators poses a significant threat. Recent findings underscore that illegal gambling platforms control a staggering percentage of the market, underlining the urgency for regulatory oversight and consumer protection. The Impact of Illegal...
Continue Reading
Color Street Expands Its Omnichannel Strategy TikTok Shop Marks a New Chapter for the Global Beauty Brand Color Street, the international beauty brand renowned for its innovative offerings in nail color, nail care, and cosmetics, has taken a significant leap by launching its official shop on TikTok. This initiative highlights the company's commitment to an omnichannel...
Continue Reading